Acta medica academica最新文献_第7页

Spontaneous Bleeding in Vestibular Schwannoma in Patients on Oral Anticoagulant Therapy: Report of Two Cases and Review of Literature. 口服抗凝药患者的前庭神经丛瘤自发性出血：两例病例报告和文献综述。

Q3 Medicine

Acta medica academica

Pub Date : 2024-04-01 DOI: 10.5644/ama2006-124.426

Mirza Pojskić, Domagoj Gajski, Alisa Arnautović, Kenan I Arnautović

Objective: Anticoagulant therapy is a risk factor for repeated intratumoral hemorrhage and acute enlargement of a vestibular schwannoma (VS) with neurological deficits. Therefore, we describe two cases of patients on oral anticoagulant therapy with intratumoral hemorrhage in which anticoagulant therapy prior to surgical resection was discontinued. We also discuss other similar cases from the literature since this is a rare event.

Case reports: We described the two cases of intratumoral hemorrhage in acoustic neurinoma and conducted a literature review of similar cases of patients with intratumoral hemorrhage in acoustic neurinoma who were also on oral anticoagulants. Both patients presented with CN-VII palsy prior to surgery; both also fully re-covered after surgery except for hearing loss on the tumor side. Our literature review found 50 cases of VS (reported as vestibular schwannomas in the literature) with intratumoral hemorrhage. From this total, 11 patients used oral anticoagulant therapy with reported poor outcomes and high mortality; 9 of these 11 cases were reported in the past 20 years. The incidence is expected to rise due to increased use of anticoagulant therapy due to onset of atrial fibrillation, atherosclerosis, and thromboembolism from longer human lifespan.

Conclusion: Anticoagulant therapy represents a risk factor for intratumoral hemorrhage and acute enlargement of VS tumor mass with neurological deficits.

目的：抗凝治疗是前庭分裂瘤（VS）反复发生瘤内出血和急性增大并伴有神经功能障碍的危险因素。因此，我们描述了两例口服抗凝剂治疗的患者在手术切除前停止抗凝剂治疗后出现瘤内出血的病例。我们还讨论了文献中的其他类似病例，因为这种情况非常罕见：我们描述了两例听神经瘤瘤腔内出血病例，并对听神经瘤瘤腔内出血患者同时口服抗凝剂的类似病例进行了文献回顾。这两名患者在手术前都出现了 CN-VII 麻痹，手术后除肿瘤一侧听力下降外，其余均完全恢复。我们在文献综述中发现 50 例 VS（文献中报告为前庭分裂瘤）伴有瘤内出血。其中有 11 例患者使用了口服抗凝疗法，据报道疗效不佳，死亡率较高；这 11 例中有 9 例是在过去 20 年中报道的。由于人类寿命延长导致心房颤动、动脉粥样硬化和血栓栓塞症的发生，使用抗凝疗法的人数增加，预计发病率还会上升：结论：抗凝治疗是导致瘤内出血和 VS 肿瘤肿块急性增大并伴有神经功能障碍的危险因素。

{"title":"Spontaneous Bleeding in Vestibular Schwannoma in Patients on Oral Anticoagulant Therapy: Report of Two Cases and Review of Literature.","authors":"Mirza Pojskić, Domagoj Gajski, Alisa Arnautović, Kenan I Arnautović","doi":"10.5644/ama2006-124.426","DOIUrl":"10.5644/ama2006-124.426","url":null,"abstract":"Objective: Anticoagulant therapy is a risk factor for repeated intratumoral hemorrhage and acute enlargement of a vestibular schwannoma (VS) with neurological deficits. Therefore, we describe two cases of patients on oral anticoagulant therapy with intratumoral hemorrhage in which anticoagulant therapy prior to surgical resection was discontinued. We also discuss other similar cases from the literature since this is a rare event.Case reports: We described the two cases of intratumoral hemorrhage in acoustic neurinoma and conducted a literature review of similar cases of patients with intratumoral hemorrhage in acoustic neurinoma who were also on oral anticoagulants. Both patients presented with CN-VII palsy prior to surgery; both also fully re-covered after surgery except for hearing loss on the tumor side. Our literature review found 50 cases of VS (reported as vestibular schwannomas in the literature) with intratumoral hemorrhage. From this total, 11 patients used oral anticoagulant therapy with reported poor outcomes and high mortality; 9 of these 11 cases were reported in the past 20 years. The incidence is expected to rise due to increased use of anticoagulant therapy due to onset of atrial fibrillation, atherosclerosis, and thromboembolism from longer human lifespan.Conclusion: Anticoagulant therapy represents a risk factor for intratumoral hemorrhage and acute enlargement of VS tumor mass with neurological deficits.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":" ","pages":"90-101"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review. 瑞戈非尼和 Nivolumab 对无法切除的肝细胞癌患者的疗效和安全性比较：系统回顾

Q3 Medicine

Acta medica academica

Pub Date : 2024-04-01 DOI: 10.5644/ama2006-124.443

Darmadi Darmadi, Taufik Sungkar, Cennikon Pakpahan, Sem Samuel Surja

Objective: This systematic review aimed to compare the efficacy and safety of regorafenib and nivolumab, two FDA-approved second-line treatments for unresectable Hepatocellular Carcinoma (HCC).

Methods: Literature comparing the efficacy and safety of regorafenib and nivolumab in unresectable HCC patients was systematically searched across seven databases, including: PubMed, SCOPUS, Cochrane Database of Systematic Reviews, ScienceDirect, EBSCOhost, EMBASE, and ProQuest, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The search was done on April 2nd, 2023. Study quality and risk of bias were assessed using the Agency for Healthcare Research and Quality (AHRQ) and ROBINS-1 tools. The selected studies were included in the qualitative data synthesis.

Results: Three trials found that HCC patients taking nivolumab had statistically insignificantly longer OS, TTP, and progression-free survival than those on regorafenib. Nivolumab increased ORR, with largely partial responses, and mixed DCR, with little statistical significance. All three studies showed that nivolumab had fewer side effects and improved tolerance.

Discussion: Three retrospective cohort studies with a total of 383 regorafenib-receiving cohorts and 230 nivolumab-receiving cohorts were included in the qualitative analysis. Nivolumab was found to be superior in regards of longer overall survival, longer time to progression, higher objective response rate, and lower adverse event occurrence. However, statistical significance was not achieved in most of the parameters.

Conclusions: The use of nivolumab is preferable as the second-line systemic therapy for unresectable HCC. More high-quality studies are urgently needed to generate quantitative analysis, and to encourage the formation of guidelines for second-line systemic therapy.

目的：本系统性综述旨在比较瑞戈非尼和尼伐单抗的疗效和安全性，这两种药物是美国食品药品管理局批准的治疗不可切除性肝细胞癌（HCC）的二线疗法：我们在七个数据库中系统地检索了比较瑞戈非尼和 nivolumab 在不可切除的 HCC 患者中的疗效和安全性的文献，这些数据库包括：PubMed、SCOPUS、Nivolumab 和 Norafenib：采用《系统综述和荟萃分析首选报告项目》（Preferred Reporting Items for Systematic Reviews and Meta-Analyses，PRISMA）2020 指南，在 PubMed、SCOPUS、Cochrane 系统综述数据库、ScienceDirect、EBSCOhost、EMBASE 和 ProQuest 等七个数据库中进行了系统检索。检索于 2023 年 4 月 2 日完成。研究质量和偏倚风险采用美国医疗保健研究与质量机构（AHRQ）和 ROBINS-1 工具进行评估。所选研究被纳入定性数据综合：三项试验发现，与服用瑞戈非尼的患者相比，服用尼伐单抗的HCC患者的OS、TTP和无进展生存期的延长在统计学上并不显著。Nivolumab提高了ORR（大部分为部分应答）和DCR（混合DCR），但统计意义不大。三项研究均显示，nivolumab的副作用更少，耐受性更好：讨论：三项回顾性队列研究共纳入了383个接受瑞戈非尼治疗的队列和230个接受尼伐单抗治疗的队列，并进行了定性分析。研究发现，Nivolumab在总生存期更长、进展时间更长、客观反应率更高和不良反应发生率更低等方面更具优势。然而，大多数参数都没有统计学意义：结论：使用 nivolumab 作为不可切除 HCC 的二线系统疗法是可取的。结论：使用 nivolumab 作为不可切除 HCC 的二线系统疗法是可取的，但迫切需要更多高质量的研究来进行定量分析，并鼓励制定二线系统疗法指南。

{"title":"An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review.","authors":"Darmadi Darmadi, Taufik Sungkar, Cennikon Pakpahan, Sem Samuel Surja","doi":"10.5644/ama2006-124.443","DOIUrl":"10.5644/ama2006-124.443","url":null,"abstract":"Objective: This systematic review aimed to compare the efficacy and safety of regorafenib and nivolumab, two FDA-approved second-line treatments for unresectable Hepatocellular Carcinoma (HCC).Methods: Literature comparing the efficacy and safety of regorafenib and nivolumab in unresectable HCC patients was systematically searched across seven databases, including: PubMed, SCOPUS, Cochrane Database of Systematic Reviews, ScienceDirect, EBSCOhost, EMBASE, and ProQuest, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The search was done on April 2nd, 2023. Study quality and risk of bias were assessed using the Agency for Healthcare Research and Quality (AHRQ) and ROBINS-1 tools. The selected studies were included in the qualitative data synthesis.Results: Three trials found that HCC patients taking nivolumab had statistically insignificantly longer OS, TTP, and progression-free survival than those on regorafenib. Nivolumab increased ORR, with largely partial responses, and mixed DCR, with little statistical significance. All three studies showed that nivolumab had fewer side effects and improved tolerance.Discussion: Three retrospective cohort studies with a total of 383 regorafenib-receiving cohorts and 230 nivolumab-receiving cohorts were included in the qualitative analysis. Nivolumab was found to be superior in regards of longer overall survival, longer time to progression, higher objective response rate, and lower adverse event occurrence. However, statistical significance was not achieved in most of the parameters.Conclusions: The use of nivolumab is preferable as the second-line systemic therapy for unresectable HCC. More high-quality studies are urgently needed to generate quantitative analysis, and to encourage the formation of guidelines for second-line systemic therapy.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"53 1","pages":"46-58"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11237911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Entrapment of the Subscapular Artery between the Radial Nerve and the Posterior Wall of the Axilla: An Anatomical Variation with Clinical Significance 桡神经和腋窝后壁之间的肩胛下动脉夹层：具有临床意义的解剖变异

Q3 Medicine

Acta medica academica

Pub Date : 2024-03-25 DOI: 10.5644/ama2006-124.435

Dimitra Daskalopoulou, D. Chrysikos, A. Samolis, G. Tsakotos, Amir Shihada, Maria Piagkou, Theodore Troupis

Objective. The subscapular artery vascularizes a substantial region of the thoracic wall, and the significance of its distribution is well depicted in the diversity of reconstructive procedures that rely on its blood supply. The aim of this study is to present an uncommon anatomical variation of the artery and discuss the clinical implications of its presence. Case Report. This case report depicts a rare variant of compression and the kinking of the subscapular artery by the radial nerve on the posterior wall of the axilla that was encountered during dissection of a male cadaver of Greek origin. Conclusion. The use of autologous tissues in the reconstruction of defects and treatment of lymphedema is expanding, so the need to establish safer surgical dissections is also becoming more apparent. The case of entrapment of the subscapular artery by the radial nerve is extremely rare, however, utiliz- ing tissues perfused by this artery for reconstructive purposes could potentially be futile and unsuccessful due to the inadequate blood supply or vessel thrombosis. Hence, the surgeon should adapt the treatment plan according to preoperative findings, as the presence of anatomical variants should always be suspected.

目的。肩胛下动脉支配着胸壁的大部分区域，其分布的重要性充分体现在依赖其供血的各种整形手术中。本研究旨在介绍肩胛下动脉的一种不常见的解剖变异，并讨论其存在的临床意义。病例报告。本病例报告描述了在解剖一具希腊裔男性尸体时遇到的肩胛下动脉受桡神经压迫并在腋窝后壁扭结的罕见变异。结论自体组织在重建缺损和治疗淋巴水肿方面的应用正在不断扩大，因此建立更安全的手术解剖的必要性也变得越来越明显。肩胛下动脉被桡神经卡住的病例极为罕见，然而，利用该动脉灌注的组织进行重建可能会因供血不足或血管血栓形成而徒劳无功或失败。因此，外科医生应根据术前检查结果调整治疗方案，因为应始终怀疑解剖变异的存在。

{"title":"Entrapment of the Subscapular Artery between the Radial Nerve and the Posterior Wall of the Axilla: An Anatomical Variation with Clinical Significance","authors":"Dimitra Daskalopoulou, D. Chrysikos, A. Samolis, G. Tsakotos, Amir Shihada, Maria Piagkou, Theodore Troupis","doi":"10.5644/ama2006-124.435","DOIUrl":"https://doi.org/10.5644/ama2006-124.435","url":null,"abstract":"Objective. The subscapular artery vascularizes a substantial region of the thoracic wall, and the significance of its distribution is well depicted in the diversity of reconstructive procedures that rely on its blood supply. The aim of this study is to present an uncommon anatomical variation of the artery and discuss the clinical implications of its presence. \u0000Case Report. This case report depicts a rare variant of compression and the kinking of the subscapular artery by the radial nerve on the posterior wall of the axilla that was encountered during dissection of a male cadaver of Greek origin. \u0000Conclusion. The use of autologous tissues in the reconstruction of defects and treatment of lymphedema is expanding, so the need to establish safer surgical dissections is also becoming more apparent. The case of entrapment of the subscapular artery by the radial nerve is extremely rare, however, utiliz- ing tissues perfused by this artery for reconstructive purposes could potentially be futile and unsuccessful due to the inadequate blood supply or vessel thrombosis. Hence, the surgeon should adapt the treatment plan according to preoperative findings, as the presence of anatomical variants should always be suspected.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":" 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140385005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The More Intensive the Diagnostic Workup, the More Likely It Is That the Cause of Coccygodynia Can Be Clarified 诊断工作越深入，越有可能明确尾骨痛的病因

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-08 DOI: 10.5644/ama2006-124.429

J. Finsterer

No abstract available.

无摘要。

引用次数: 0

The More Intensive the Diagnostic Workup, the More Likely It Is That the Cause of Coccygodynia Can Be Clarified 诊断工作越深入，越有可能明确尾骨痛的病因

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-08 DOI: 10.5644/ama2006-124.429

J. Finsterer

No abstract available.

无摘要。

引用次数: 0

Vitamin D-Binding Protein and the Role of its Gene Polymorphisms in the Mortality of Sepsis Patients 维生素 D 结合蛋白及其基因多态性在败血症患者死亡率中的作用

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-01 DOI: 10.5644/ama2006-124.428

Liliriawati Ananta Kahar, Y. Yusrawati, Jamsari Jamsari, T. Maskoen, Kornelis Aribowo, Wiwi Monika Sari

Objective. This study aimed to determine the role of vitamin D-binding protein (VDBP) gene polymorphisms (especially at locus rs7041), vitamin D-binding protein levels, and vitamin D levels in mortality in sepsis patients. Patients and Methods. We performed the analytic observational study with a case-control approach. A total of 80 patients were included in this study, 40 patients were grouped as the case group and 40 patients were grouped as the control group. The patients were diagnosed with sepsis and treated in the Intensive Care Unit (ICU), M. Djamil Hospital, Indonesia. The VDBP rs7041 gene polymorphism was analyzed using the polymerase chain reaction procedure. VDBP and vitamin D levels were examined using the enzyme-linked immunosorbent assay (ELISA) method. Results. The case group showed lower mean vitamin D and VDBP levels than the con- trol group (P<0.05). There were more variations in the rs7041 gene VDBP (mutant) locus in the case group than in the control group, and this difference was considered statistically significant, P<0.05. The results of this study indicate that the occurrence of polymorphism or variations at locus rs7401 (mutant) causes a decrease in VDBP and vitamin D levels. A decrease in vitamin D levels correlates with the incidence of mortality in sepsis patients. Conclusion. Polymorphism gene VDBP at locus rs7041 causes a decrease in the production of VDBP, a vitamin D carrier protein.

研究目的本研究旨在确定维生素 D 结合蛋白（VDBP）基因多态性（尤其是位点 rs7041）、维生素 D 结合蛋白水平和维生素 D 水平在败血症患者死亡率中的作用。患者和方法。我们采用病例对照方法进行了分析性观察研究。本研究共纳入 80 例患者，其中 40 例为病例组，40 例为对照组。这些患者被诊断为败血症，并在印度尼西亚 M. Djamil 医院重症监护室（ICU）接受治疗。采用聚合酶链反应程序分析了 VDBP rs7041 基因多态性。采用酶联免疫吸附试验（ELISA）方法检测VDBP和维生素D水平。结果显示病例组的维生素 D 和 VDBP 平均水平低于对照组（P<0.05）。病例组 VDBP（突变）基因 rs7041 位点的变异多于对照组，差异有统计学意义（P<0.05）。本研究结果表明，基因位点 rs7401（突变体）的多态性或变异会导致 VDBP 和维生素 D 水平下降。维生素 D 水平的降低与败血症患者的死亡率相关。结论基因 VDBP 位点 rs7041 的多态性会导致维生素 D 载体蛋白 VDBP 的生成减少。

{"title":"Vitamin D-Binding Protein and the Role of its Gene Polymorphisms in the Mortality of Sepsis Patients","authors":"Liliriawati Ananta Kahar, Y. Yusrawati, Jamsari Jamsari, T. Maskoen, Kornelis Aribowo, Wiwi Monika Sari","doi":"10.5644/ama2006-124.428","DOIUrl":"https://doi.org/10.5644/ama2006-124.428","url":null,"abstract":"Objective. This study aimed to determine the role of vitamin D-binding protein (VDBP) gene polymorphisms (especially at locus rs7041), vitamin D-binding protein levels, and vitamin D levels in mortality in sepsis patients. \u0000Patients and Methods. We performed the analytic observational study with a case-control approach. A total of 80 patients were included in this study, 40 patients were grouped as the case group and 40 patients were grouped as the control group. The patients were diagnosed with sepsis and treated in the Intensive Care Unit (ICU), M. Djamil Hospital, Indonesia. The VDBP rs7041 gene polymorphism was analyzed using the polymerase chain reaction procedure. VDBP and vitamin D levels were examined using the enzyme-linked immunosorbent assay (ELISA) method. \u0000Results. The case group showed lower mean vitamin D and VDBP levels than the con- trol group (P<0.05). There were more variations in the rs7041 gene VDBP (mutant) locus in the case group than in the control group, and this difference was considered statistically significant, P<0.05. The results of this study indicate that the occurrence of polymorphism or variations at locus rs7401 (mutant) causes a decrease in VDBP and vitamin D levels. A decrease in vitamin D levels correlates with the incidence of mortality in sepsis patients. \u0000Conclusion. Polymorphism gene VDBP at locus rs7041 causes a decrease in the production of VDBP, a vitamin D carrier protein.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"93 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139878772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vitamin D-Binding Protein and the Role of its Gene Polymorphisms in the Mortality of Sepsis Patients 维生素 D 结合蛋白及其基因多态性在败血症患者死亡率中的作用

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-01 DOI: 10.5644/ama2006-124.428

Liliriawati Ananta Kahar, Y. Yusrawati, Jamsari Jamsari, T. Maskoen, Kornelis Aribowo, Wiwi Monika Sari

Objective. This study aimed to determine the role of vitamin D-binding protein (VDBP) gene polymorphisms (especially at locus rs7041), vitamin D-binding protein levels, and vitamin D levels in mortality in sepsis patients. Patients and Methods. We performed the analytic observational study with a case-control approach. A total of 80 patients were included in this study, 40 patients were grouped as the case group and 40 patients were grouped as the control group. The patients were diagnosed with sepsis and treated in the Intensive Care Unit (ICU), M. Djamil Hospital, Indonesia. The VDBP rs7041 gene polymorphism was analyzed using the polymerase chain reaction procedure. VDBP and vitamin D levels were examined using the enzyme-linked immunosorbent assay (ELISA) method. Results. The case group showed lower mean vitamin D and VDBP levels than the con- trol group (P<0.05). There were more variations in the rs7041 gene VDBP (mutant) locus in the case group than in the control group, and this difference was considered statistically significant, P<0.05. The results of this study indicate that the occurrence of polymorphism or variations at locus rs7401 (mutant) causes a decrease in VDBP and vitamin D levels. A decrease in vitamin D levels correlates with the incidence of mortality in sepsis patients. Conclusion. Polymorphism gene VDBP at locus rs7041 causes a decrease in the production of VDBP, a vitamin D carrier protein.

研究目的本研究旨在确定维生素 D 结合蛋白（VDBP）基因多态性（尤其是位点 rs7041）、维生素 D 结合蛋白水平和维生素 D 水平在败血症患者死亡率中的作用。患者和方法。我们采用病例对照方法进行了分析性观察研究。本研究共纳入 80 例患者，其中 40 例为病例组，40 例为对照组。这些患者被诊断为败血症，并在印度尼西亚 M. Djamil 医院重症监护室（ICU）接受治疗。采用聚合酶链反应程序分析了 VDBP rs7041 基因多态性。采用酶联免疫吸附试验（ELISA）方法检测VDBP和维生素D水平。结果显示病例组的维生素 D 和 VDBP 平均水平低于对照组（P<0.05）。病例组 VDBP（突变）基因 rs7041 位点的变异多于对照组，差异有统计学意义（P<0.05）。本研究结果表明，基因位点 rs7401（突变体）的多态性或变异会导致 VDBP 和维生素 D 水平下降。维生素 D 水平的降低与败血症患者的死亡率相关。结论基因 VDBP 位点 rs7041 的多态性会导致维生素 D 载体蛋白 VDBP 的生成减少。

{"title":"Vitamin D-Binding Protein and the Role of its Gene Polymorphisms in the Mortality of Sepsis Patients","authors":"Liliriawati Ananta Kahar, Y. Yusrawati, Jamsari Jamsari, T. Maskoen, Kornelis Aribowo, Wiwi Monika Sari","doi":"10.5644/ama2006-124.428","DOIUrl":"https://doi.org/10.5644/ama2006-124.428","url":null,"abstract":"Objective. This study aimed to determine the role of vitamin D-binding protein (VDBP) gene polymorphisms (especially at locus rs7041), vitamin D-binding protein levels, and vitamin D levels in mortality in sepsis patients. \u0000Patients and Methods. We performed the analytic observational study with a case-control approach. A total of 80 patients were included in this study, 40 patients were grouped as the case group and 40 patients were grouped as the control group. The patients were diagnosed with sepsis and treated in the Intensive Care Unit (ICU), M. Djamil Hospital, Indonesia. The VDBP rs7041 gene polymorphism was analyzed using the polymerase chain reaction procedure. VDBP and vitamin D levels were examined using the enzyme-linked immunosorbent assay (ELISA) method. \u0000Results. The case group showed lower mean vitamin D and VDBP levels than the con- trol group (P<0.05). There were more variations in the rs7041 gene VDBP (mutant) locus in the case group than in the control group, and this difference was considered statistically significant, P<0.05. The results of this study indicate that the occurrence of polymorphism or variations at locus rs7401 (mutant) causes a decrease in VDBP and vitamin D levels. A decrease in vitamin D levels correlates with the incidence of mortality in sepsis patients. \u0000Conclusion. Polymorphism gene VDBP at locus rs7041 causes a decrease in the production of VDBP, a vitamin D carrier protein.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"14 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139818929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia 诱导治疗第 15 天时的最小残留病灶对急性淋巴细胞白血病患儿存活率的影响

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-01 DOI: 10.5644/ama2006-124.427

Jelica Samardžić-Predojević, Biljana Đurđević-Banjac, Dragana Malcic-Zanic

Objective. The aim of the study was to evaluate the impact of minimal residual disease (MRD) on day 15 of induction therapy (d15) on the treatment outcome in children with acute lymphoblastic leukemia (ALL). Materials and Methods. The study included 74 patients (1-18 years) with ALL, who were treated at the Pediatric Clinic of the University Clinical Center Banja Luka from January 2011 to May 2021. All patients were treated according to ALL IC-BFM 2009 protocol. MRD on bone mar- row was assessed d15, using the multiparameter flow cytometry method (FCM). Results. Of all, 59.46% of patients had MRD d15 0.1−10%, MRD<0.1% had 18.92% of patients, and 21.62% had MRD >10%. Patients with the lowest MRD had the highest 5-year overall survival (OS) and event-free survival (89.5% and 91% respectively) and the lowest cumulative risk for relapse or death (9.7% and 8.1%), in contrast to patients with MRD>10% in whom OS was 80.0%, and the risk of recurrence is 20%. Predicted MRD d15 was significantly associated with prednisone response assessed in the peripheral blood on day 8 (P<0.001) and statistically significantly positive correlation (r=0.498; P<0.001) was found. Conclusion. MRD measurement d15 has a great prognostic significance for patients in the standard and high risk groups, but not for patients in the intermediate risk group. The introduction of additional testing is necessary for better identification of patients with an increased risk of disease recurrence.

研究目的本研究旨在评估诱导治疗第15天（d15）的最小残留病（MRD）对急性淋巴细胞白血病（ALL）患儿治疗结果的影响。材料与方法。研究共纳入74名ALL患者（1-18岁），他们于2011年1月至2021年5月在巴尼亚卢卡大学临床中心儿科诊所接受治疗。所有患者均按照2009年ALL IC-BFM方案接受治疗。采用多参数流式细胞术（FCM）方法，在第15天评估骨水泥上的MRD。结果。59.46%的患者MRD d15为0.1-10%，MRD为10%。MRD最低的患者5年总生存期（OS）和无事件生存期最高（分别为89.5%和91%），复发或死亡累积风险最低（分别为9.7%和8.1%），而MRD>10%的患者OS为80.0%，复发风险为20%。预测的MRD d15与第8天外周血中评估的泼尼松反应显著相关（P<0.001），并在统计学上发现显著正相关（r=0.498；P<0.001）。结论MRD 测量 d15 对标准组和高风险组患者的预后意义重大，但对中度风险组患者的预后意义不大。为了更好地识别疾病复发风险增加的患者，有必要进行额外的检测。

{"title":"Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia","authors":"Jelica Samardžić-Predojević, Biljana Đurđević-Banjac, Dragana Malcic-Zanic","doi":"10.5644/ama2006-124.427","DOIUrl":"https://doi.org/10.5644/ama2006-124.427","url":null,"abstract":"Objective. The aim of the study was to evaluate the impact of minimal residual disease (MRD) on day 15 of induction therapy (d15) on the treatment outcome in children with acute lymphoblastic leukemia (ALL). \u0000Materials and Methods. The study included 74 patients (1-18 years) with ALL, who were treated at the Pediatric Clinic of the University Clinical Center Banja Luka from January 2011 to May 2021. All patients were treated according to ALL IC-BFM 2009 protocol. MRD on bone mar- row was assessed d15, using the multiparameter flow cytometry method (FCM). \u0000Results. Of all, 59.46% of patients had MRD d15 0.1−10%, MRD<0.1% had 18.92% of patients, and 21.62% had MRD >10%. Patients with the lowest MRD had the highest 5-year overall survival (OS) and event-free survival (89.5% and 91% respectively) and the lowest cumulative risk for relapse or death (9.7% and 8.1%), in contrast to patients with MRD>10% in whom OS was 80.0%, and the risk of recurrence is 20%. Predicted MRD d15 was significantly associated with prednisone response assessed in the peripheral blood on day 8 (P<0.001) and statistically significantly positive correlation (r=0.498; P<0.001) was found. \u0000Conclusion. MRD measurement d15 has a great prognostic significance for patients in the standard and high risk groups, but not for patients in the intermediate risk group. The introduction of additional testing is necessary for better identification of patients with an increased risk of disease recurrence.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"2017 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139879095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia 诱导治疗第 15 天时的最小残留病灶对急性淋巴细胞白血病患儿存活率的影响

Q3 Medicine

Acta medica academica

Pub Date : 2024-02-01 DOI: 10.5644/ama2006-124.427

Jelica Samardžić-Predojević, Biljana Đurđević-Banjac, Dragana Malcic-Zanic

Objective. The aim of the study was to evaluate the impact of minimal residual disease (MRD) on day 15 of induction therapy (d15) on the treatment outcome in children with acute lymphoblastic leukemia (ALL). Materials and Methods. The study included 74 patients (1-18 years) with ALL, who were treated at the Pediatric Clinic of the University Clinical Center Banja Luka from January 2011 to May 2021. All patients were treated according to ALL IC-BFM 2009 protocol. MRD on bone mar- row was assessed d15, using the multiparameter flow cytometry method (FCM). Results. Of all, 59.46% of patients had MRD d15 0.1−10%, MRD<0.1% had 18.92% of patients, and 21.62% had MRD >10%. Patients with the lowest MRD had the highest 5-year overall survival (OS) and event-free survival (89.5% and 91% respectively) and the lowest cumulative risk for relapse or death (9.7% and 8.1%), in contrast to patients with MRD>10% in whom OS was 80.0%, and the risk of recurrence is 20%. Predicted MRD d15 was significantly associated with prednisone response assessed in the peripheral blood on day 8 (P<0.001) and statistically significantly positive correlation (r=0.498; P<0.001) was found. Conclusion. MRD measurement d15 has a great prognostic significance for patients in the standard and high risk groups, but not for patients in the intermediate risk group. The introduction of additional testing is necessary for better identification of patients with an increased risk of disease recurrence.

研究目的本研究旨在评估诱导治疗第15天（d15）的最小残留病（MRD）对急性淋巴细胞白血病（ALL）患儿治疗结果的影响。材料与方法。研究共纳入74名ALL患者（1-18岁），他们于2011年1月至2021年5月在巴尼亚卢卡大学临床中心儿科诊所接受治疗。所有患者均按照2009年ALL IC-BFM方案接受治疗。采用多参数流式细胞术（FCM）方法，在第15天评估骨水泥上的MRD。结果。59.46%的患者MRD d15为0.1-10%，MRD为10%。MRD最低的患者5年总生存期（OS）和无事件生存期最高（分别为89.5%和91%），复发或死亡累积风险最低（分别为9.7%和8.1%），而MRD>10%的患者OS为80.0%，复发风险为20%。预测的MRD d15与第8天外周血中评估的泼尼松反应显著相关（P<0.001），并在统计学上发现显著正相关（r=0.498；P<0.001）。结论MRD 测量 d15 对标准组和高风险组患者的预后意义重大，但对中度风险组患者的预后意义不大。为了更好地识别疾病复发风险增加的患者，有必要进行额外的检测。

{"title":"Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia","authors":"Jelica Samardžić-Predojević, Biljana Đurđević-Banjac, Dragana Malcic-Zanic","doi":"10.5644/ama2006-124.427","DOIUrl":"https://doi.org/10.5644/ama2006-124.427","url":null,"abstract":"Objective. The aim of the study was to evaluate the impact of minimal residual disease (MRD) on day 15 of induction therapy (d15) on the treatment outcome in children with acute lymphoblastic leukemia (ALL). \u0000Materials and Methods. The study included 74 patients (1-18 years) with ALL, who were treated at the Pediatric Clinic of the University Clinical Center Banja Luka from January 2011 to May 2021. All patients were treated according to ALL IC-BFM 2009 protocol. MRD on bone mar- row was assessed d15, using the multiparameter flow cytometry method (FCM). \u0000Results. Of all, 59.46% of patients had MRD d15 0.1−10%, MRD<0.1% had 18.92% of patients, and 21.62% had MRD >10%. Patients with the lowest MRD had the highest 5-year overall survival (OS) and event-free survival (89.5% and 91% respectively) and the lowest cumulative risk for relapse or death (9.7% and 8.1%), in contrast to patients with MRD>10% in whom OS was 80.0%, and the risk of recurrence is 20%. Predicted MRD d15 was significantly associated with prednisone response assessed in the peripheral blood on day 8 (P<0.001) and statistically significantly positive correlation (r=0.498; P<0.001) was found. \u0000Conclusion. MRD measurement d15 has a great prognostic significance for patients in the standard and high risk groups, but not for patients in the intermediate risk group. The introduction of additional testing is necessary for better identification of patients with an increased risk of disease recurrence.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"156 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139819336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Animal Model of Cisplatin-Induced Oral Mucositis: Dose Optimization 顺铂诱发口腔黏膜炎的动物模型：剂量优化

Q3 Medicine

Acta medica academica

Pub Date : 2024-01-19 DOI: 10.5644/ama2006-124.422

Oke Kadarullah, D. Tamtomo, Brian Wasita, Made Setiamika

Objective. The present study aimed to develop and validate an animal model of chemotherapy-induced oral mucositis due to cisplatin administration. Materials and Methods. Oral mucositis was induced in Wistar rats by cisplatin. Twenty healthy male Wistar rats were divided into four groups: a control group, and cisplatin 3 mg/kgBW (D1), cisplatin 5 mg/kgBW (D2), and cis- platin 6 mg/kgBW groups (D3). The D1, D2, and D3 groups received the cisplatin intraperitoneally on days 1, 3, and 5, whereas the control group did not receive anything. On day 7 and day 14 the entire experiment was terminated in all groups and the changes in body weight, oral mucositis grades, and histopathological scores were evaluated. Results. Cisplatin administration created a strong oral mucositis effect on groups D2 and D3. All the cisplatin doses decreased the rats’ body weight by day 14. The worst oral mucositis grades and histopathological scores resulted from the administration of cisplatin at a dose of 5 mg/kgBW. Conclusions. In conclusion the cisplatin 5 mg/kgBW administered on days 1, 3, and 5 by intraperitoneal administration was the optimum dose to induce oral mucositis.

研究目的本研究旨在建立并验证顺铂给药导致化疗诱发口腔黏膜炎的动物模型。材料和方法。顺铂诱导 Wistar 大鼠口腔黏膜炎。20 只健康雄性 Wistar 大鼠被分为四组：对照组、顺铂 3 毫克/千克体重组（D1）、顺铂 5 毫克/千克体重组（D2）和顺铂 6 毫克/千克体重组（D3）。D1、D2和D3组在第1、3和5天腹腔注射顺铂，而对照组则不注射任何药物。第 7 天和第 14 天，终止所有组的整个实验，并评估体重、口腔黏膜炎等级和组织病理学评分的变化。结果顺铂对 D2 和 D3 组产生了强烈的口腔黏膜炎效应。到第 14 天时，所有顺铂剂量的大鼠体重都有所下降。顺铂剂量为 5 毫克/千克体重时，口腔黏膜炎等级和组织病理学评分最差。结论总之，在第 1、3 和 5 天腹腔注射 5 毫克/千克体重的顺铂是诱发口腔黏膜炎的最佳剂量。

{"title":"Animal Model of Cisplatin-Induced Oral Mucositis: Dose Optimization","authors":"Oke Kadarullah, D. Tamtomo, Brian Wasita, Made Setiamika","doi":"10.5644/ama2006-124.422","DOIUrl":"https://doi.org/10.5644/ama2006-124.422","url":null,"abstract":"Objective. The present study aimed to develop and validate an animal model of chemotherapy-induced oral mucositis due to cisplatin administration. \u0000Materials and Methods. Oral mucositis was induced in Wistar rats by cisplatin. Twenty healthy male Wistar rats were divided into four groups: a control group, and cisplatin 3 mg/kgBW (D1), cisplatin 5 mg/kgBW (D2), and cis- platin 6 mg/kgBW groups (D3). The D1, D2, and D3 groups received the cisplatin intraperitoneally on days 1, 3, and 5, whereas the control group did not receive anything. On day 7 and day 14 the entire experiment was terminated in all groups and the changes in body weight, oral mucositis grades, and histopathological scores were evaluated. \u0000Results. Cisplatin administration created a strong oral mucositis effect on groups D2 and D3. All the cisplatin doses decreased the rats’ body weight by day 14. The worst oral mucositis grades and histopathological scores resulted from the administration of cisplatin at a dose of 5 mg/kgBW. \u0000Conclusions. In conclusion the cisplatin 5 mg/kgBW administered on days 1, 3, and 5 by intraperitoneal administration was the optimum dose to induce oral mucositis.","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"49 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139611910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0